Litcius/Paper detail

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains

Yupanun Wutti‐in, Jatuporn Sujjitjoon, Nunghathai Sawasdee, Aussara Panya, K. Kongkla, Pornpimon Yuti, Petlada Yongpitakwattana, Chutamas Thepmalee, Mutita Junking, Thaweesak Chieochansin, Naravat Poungvarin, Montarop Yamabhai, Pa‐thai Yenchitsomanus

2022Frontiers in Oncology23 citationsDOIOpen Access PDF

Abstract

Second-generation anti-CD19-chimeric antigen receptor T cells (anti-CD19-CAR2 T cells) are effective for treating B-cell malignancies; however, anti-CD19-CAR2 T cells can induce human anti-mouse immune responses because anti-CD19 single-chain variable fragment (scFv) in the CAR molecules is derived from a murine FMC63 (mFMC63) monoclonal antibody. Consequently, the persistence of mFMC63-CAR2 T cells and their therapeutic efficiency in patients are decreased, which results in tumor relapse. In an attempt to remedy this shortcoming, we generated a new anti-CD19-CAR T cells containing fully human anti-CD19 scFv (Hu1E7-CAR4 T cells) to pre-clinically evaluate and compare with mFMC63-CAR4 T cells. The human anti-CD19 scFv (Hu1E7) was isolated from a human scFv phage display library and fused to the hinge region of CD8α, the transmembrane domain of CD28, three intracellular costimulatory domains (CD28, 4-1BB, and CD27), and a CD3ζ signaling domain (28BB27ζ). Compared to mFMC63-CAR2 T cells (BBζ) and mFMC63-CAR3 (BB27ζ), the mFMC63-CAR4 T cells (28BB27ζ) exerted superior anti-tumor activity against Raji (CD19 + ) target cell. The Hu1E7-CAR4 and mFMC63-CAR4 T cells demonstrated comparable cytotoxicity and proliferation. Interestingly, compared to mFMC63-CAR4 T cells, the Hu1E7-CAR4 T cells secreted lower levels of cytokines (IFN-γ and TNF-α), which may be due to the lower binding affinity of Hu1E7-CAR4 T cells. These findings demonstrated the successfulness in creation of a new CAR T cells containing a novel fully human-derived scFv specific to CD19 + cancer cells. In vivo studies are needed to further compare the anti-tumor efficacy and safety of Hu1E7-CAR4 T cells and mFMC63-CAR4 T cells.

Topics & Concepts

CD19CD28Molecular biologyT cellCytotoxic T cellChimeric antigen receptorInterleukin 21BiologyAntibodyChemistryImmune systemImmunologyIn vitroBiochemistryCAR-T cell therapy researchNanowire Synthesis and ApplicationsSilicon Carbide Semiconductor Technologies
Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains | Litcius